---
layout: post
title: "昂利康：异氟烷原料药通过CDE审批"
date: 2022-01-20 16:56:13 +0800
categories: cailianshe
tags: 财联社新闻
---
<!-- EM_StockImg_Start --><p style="text-align:center;"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002940&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002940_0" data-code="K 002940|0|2" data-code2="K 002940|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></p><!-- EM_StockImg_End --><p>昂利康公告，公司控股子公司海西药业异氟烷原料药通过CDE技术审评。异氟烷原料药原研是美国百特国际有限公司，用于成人和儿科患者的院内手术及门诊手术的全身麻醉的诱导和维持。</p><p class="em_media">（文章来源：财联社）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201202255222484>

[返回财联社新闻](//finews.withounder.com/category/cailianshe.html)｜[返回首页](//finews.withounder.com/)